Clinical trial
Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes (HS-IT101) for the Treatment of Advanced Solid Tumor
NCT05539768 is registered in ClinicalTrials.gov with The Affiliated Hospital of Qingdao University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes (HS-IT101) for the Treatment of Advanced Solid Tumor
- Lead sponsor
- The Affiliated Hospital of Qingdao University
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- October 8, 2022
- Completion date
- March 31, 2027
- Enrollment
- 8 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
advanced solid tumor